Cardiff Oncology, Inc.
General ticker "CRDF" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $168.0M (TTM average)
Cardiff Oncology, Inc. does not follow the US Stock Market performance with the rate: -18.9%.
Estimated limits based on current volatility of 7.5%: low 1.43$, high 1.66$
Factors to consider:
- Total employees count: 33 (+3.1%) as of 2024
- Top business risk factors: Regulatory and compliance, Economic downturns and volatility, Supply chain disruptions, Pandemic risks, Litigation risks
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.34$, 3.73$]
- 2026-12-31 to 2027-12-31 estimated range: [1.16$, 3.29$]
Financial Metrics affecting the CRDF estimates:
- Positive: with PPE of -4.1 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 0.71 > -0.60
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
Short-term CRDF quotes
Long-term CRDF plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.49MM | $0.68MM | $0.59MM |
| Operating Expenses | $45.90MM | $49.33MM | $49.55MM |
| Operating Income | $-45.41MM | $-48.65MM | $-48.96MM |
| Non-Operating Income | $3.97MM | $3.22MM | $3.11MM |
| R&D Expense | $32.86MM | $36.85MM | $35.33MM |
| Income(Loss) | $-41.44MM | $-45.43MM | $-45.85MM |
| Net Income(Loss)* | $-41.44MM | $-45.43MM | $-45.85MM |
| Stockholders Equity | $69.74MM | $82.95MM | $45.39MM |
| Assets | $81.64MM | $97.19MM | $61.88MM |
| Operating Cash Flow | $-30.89MM | $-37.69MM | $-37.92MM |
| Capital expenditure | $0.58MM | $0.08MM | $0.04MM |
| Investing Cash Flow | $36.20MM | $13.73MM | $1.34MM |
| Financing Cash Flow | $0.00MM | $53.78MM | $2.58MM |
| Earnings Per Share** | $-0.93 | $-0.95 | $-0.69 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.